drugset
drugset / Trial / NCT05532735

Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion

NCT05532735 ↗

Phase 2 Completed 16 enrolled Annexin Pharmaceuticals AB InFocus Clinical Research · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

Open-label, dose ascending safety, tolerability, and proof of concept study to evaluate the use of ANXV (human recombinant Annexin A5) in the treatment of subjects with recently diagnosed Retinal Vein Occlusion.

Timeline

Start
2022-08-24
Primary completion
2024-07-17
Completion
2024-11-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Annexin A5 Protein / enzyme biologic 1 mg Other
Subject Annexin A5 Protein / enzyme biologic 2 mg Other
Subject Annexin A5 Protein / enzyme biologic 4 mg Other
Subject Annexin A5 Protein / enzyme biologic 6 mg Other
Subject Annexin A5 Protein / enzyme biologic 8 mg Other

Indications

retinal vein occlusion